InvestorsHub Logo
Followers 5
Posts 213
Boards Moderated 0
Alias Born 08/19/2013

Re: thefamilyman post# 1667

Monday, 11/10/2014 4:09:22 PM

Monday, November 10, 2014 4:09:22 PM

Post# of 3834
Also here:




http://investor.galectintherapeutics.com/releasedetail.cfm?ReleaseID=881702

Quote:

"Based on the robust pre-clinical efficacy and positive safety, tolerability and pharmacokinetics in the Phase 1 clinical trial and a pharmacodynamic effect, the Company is in a position to design a strong Phase 2 clinical trial to assess potential surrogate endpoints that are closely associated with clinical-related outcomes in patients with cirrhosis, including hepatic venous pressure gradient (HVPG) and morphometric analysis of collagen on liver biopsies," continued Dr. Traber. "To this end, the Company recently met with the"
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent GALT News